Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Alphyn anticipates the initiation of the global Phase 2b trials of Zabalafin Hydrogel in the first quarter of 2025. Zabalafin Hydrogel has demonstrated strong efficacy and safety in Phase 2a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback